Arrow Acquisition Leads FTC to Propose Asset Divestiture

The FTC has proposed a consent order to ensure competition for two generic drugs after Watson Pharmaceuticals’ acquisition of Arrow Pharmaceuticals. The order settles charges that Watson’s purchase of Robin Hood Holdings, the owner of Arrow, would reduce the number of suppliers of two generic drugs — Parkinson’s disease treatment cabergoline and dronabinol, which is used to treat side effects of chemotherapy, the FTC says in a statement. The deadline for public comment is Jan. 4.
Generic Line